Comparative Pharmacology
Head-to-head clinical analysis: OXAZEPAM versus ZAXOPAM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXAZEPAM versus ZAXOPAM.
OXAZEPAM vs ZAXOPAM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to GABA-A receptor at benzodiazepine binding site, enhancing Cl- ion conductance and increasing inhibitory neurotransmission. Anxiolytic, sedative, hypnotic, anticonvulsant, and muscle relaxant effects.
Zaxopam is a benzodiazepine that enhances GABA-A receptor activity by binding to the benzodiazepine site, increasing chloride ion influx and causing neuronal hyperpolarization.
10-30 mg orally 3-4 times daily; maximum 120 mg/day.
10 mg orally twice daily, titrated to a maximum of 30 mg twice daily based on response and tolerability; oral route.
None Documented
None Documented
Terminal elimination half-life is 5-15 hours (mean 8 hours); no active metabolites, thus accumulation is minimal even with repeated dosing.
Clinical Note
moderateOxazepam + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Oxazepam is combined with Fluticasone propionate."
Clinical Note
moderateOxazepam + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Oxazepam."
Clinical Note
moderateOxazepam + Cyclosporine
Terminal elimination half-life is 12-15 hours, allowing for once-daily dosing in most patients.
Renal (primarily as glucuronide conjugates, with less than 1% unchanged); biliary/fecal excretion is minimal.
Renal excretion accounts for approximately 80% of the administered dose, predominantly as conjugated metabolites; biliary/fecal excretion accounts for the remaining 20%.
Category D/X
Category C
Benzodiazepine
Benzodiazepine
"The metabolism of Cyclosporine can be decreased when combined with Oxazepam."